19:10 IST
NSE
Regulatory Approval
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Dapsone Gel, 5%. This marks the company's 224th final ANDA approval.
Alembic Pharmaceuticals Ltd
- Share price
- ₹831.35
- Market cap
- ₹16,341 Cr
- Revenue (annual)
- ₹7,345 Cr
- Net profit (annual)
- ₹674.8 Cr
- P/E (TTM)
- 23.6×Sector 47.4×
- Promoter holding
- 69.87%+0.13% QoQ
- FII holding
- 4.17%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
All
Management Change 13Debt & Borrowing 9Regulatory Approval 8Merger & Restructuring 8Earnings Call 5Business Update 5Other Announcement 3Financial Results 3Results Update 2Credit Rating 2Board Meeting Date 2Annual General Meeting 2Legal & Regulatory 1Dividend 1Annual Report 1
Time
8 announcements with these filters
10:31 IST
NSE
Regulatory Approval
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Oseltamivir Phosphate Oral Suspension. The product has an estimated market size of ₹253.8 Crore.
- Value
- ₹253.8 Cr
10:50 IST
NSE
Regulatory Approval
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received final USFDA approval for Haloperidol Tablets used in treating psychotic and Tourette’s disorders. This strengthens the company's generic portfolio in the US market.
10:59 IST
BSE
Regulatory Approval
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Levothyroxine Sodium Tablets USP. The market size is estimated at ₹17942.4 Crore, strengthening the company's US generic portfolio.
- Value
- ₹17,942 Cr
10:08 IST
NSE
Regulatory Approval
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA tentative approval for Darolutamide Tablets, targeting a ₹29,972.5 Crore market. This approval strengthens the company's oncology portfolio and international growth prospects.
- Value
- ₹29,972 Cr
11:55 IST
BSE
Regulatory Approval
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Fingolimod Capsules, 0.5 mg, used for treating relapsing forms of multiple sclerosis. The product has an estimated annual market size of approximately ₹1363.0 Crore (US$ 145 million). This marks the company's 237th cumulative ANDA approval, strengthening its US generic portfolio.
- Value
- ₹1,363 Cr
11:14 IST
BSE
Regulatory Approval
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals Limited received USFDA final approval for Methotrexate Injection USP in multi-dose and single-dose vials. The drug is indicated for neoplastic diseases, rheumatoid arthritis, and severe psoriasis. This marks the company's 236th ANDA approval, strengthening its generic injectable portfolio in the US market.
12:24 IST
NSE
Regulatory Approval
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Dapagliflozin Tablets (5 mg and 10 mg), used for type 2 diabetes and heart failure. The product addresses a US$ 10,487 million (₹9,752.91 Crore) market. As a Paragraph IV applicant, Alembic is eligible for 180 days of shared generic exclusivity, marking its 217th final ANDA approval.
- Value
- ₹9,753 Cr
- Execution
- 180 days of shared generic drug exclusivity